Introduction
Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib, an oral targeted anticancer medicine that inhibits fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3.
Pemigatinib is prescribed for selected patients whose cancer has specific molecular characteristics. It is not appropriate for every type of cancer, and treatment should only begin after assessment by a qualified healthcare professional.
Taking pemigatinib correctly is important for treatment safety. Patients need to follow the prescribed dose, treatment schedule and monitoring instructions. They should also understand what to do if they miss a dose, experience vomiting or develop possible side effects.
The instructions below summarize information from the established U.S. reference-product prescribing information. The instructions supplied with the actual Pemitinib product and the patient’s prescription must also be checked.
1. Follow the Prescribed Treatment Schedule
Pemigatinib is taken by mouth. The prescribed schedule depends on the condition being treated.
For qualifying previously treated, unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or other qualifying rearrangement, the U.S. reference-product schedule is:
- Take 13.5 mg once daily for 14 consecutive days.
- Follow this with seven days without treatment.
- Repeat the schedule in 21-day cycles as directed by the treating specialist.
For qualifying relapsed or refractory myeloid/lymphoid neoplasms with an FGFR1 rearrangement, the U.S. reference-product schedule is 13.5 mg once daily continuously.
These are different treatment schedules. Patients must not choose a schedule themselves or use one condition’s instructions for another condition.
2. Take the Tablet as Directed
The reference product is an oral tablet.
The tablet should be swallowed whole with water. It should not be crushed, chewed, split or dissolved unless the official instructions for the actual product specifically permit a different method.
Patients should check the product packaging and prescription to confirm the correct strength and dosage form.
Taking the wrong strength or changing the tablet without professional advice may lead to an incorrect dose.
3. Taking Pemigatinib With or Without Food
Under U.S. reference-product instructions, pemigatinib may be taken with or without food.
Patients should follow the instructions provided with their actual product and maintain a consistent routine that helps them remember each scheduled dose.
Food does not replace the need to follow the prescribed treatment schedule.
Patients should discuss dietary restrictions and possible food interactions with their healthcare professional.
4. Choose a Consistent Time
Taking the medicine at approximately the same time each scheduled day may help patients maintain their treatment routine.
A daily reminder or written medication schedule can help prevent accidental missed doses.
Patients should understand whether their treatment includes scheduled rest days. For the intermittent cholangiocarcinoma schedule, the seven-day break is part of the prescribed cycle, not an instruction to stop treatment permanently.
5. What to Do If a Dose Is Missed
If a patient forgets to take a scheduled dose, the U.S. reference-product instructions specify that a missed dose may be taken if the patient remembers within four hours of the scheduled time.
If more than four hours have passed, the missed dose should be skipped and the next dose taken at the usual scheduled time.
Patients should not take an extra dose to compensate for a missed dose.
If there is uncertainty about the treatment schedule, the patient should contact the treating healthcare professional or pharmacist.
6. What to Do If Vomiting Occurs
If vomiting occurs after taking pemigatinib, patients should not take another tablet to replace the dose.
The next dose should be taken at the usual scheduled time.
Taking an additional tablet without instructions may result in an unintended higher dose.
Persistent vomiting should be discussed with a healthcare professional, particularly if it causes dehydration or makes it difficult to maintain normal food and fluid intake.
7. Do Not Change the Dose Yourself
The prescribed dose may need to be adjusted if certain adverse reactions occur or if the patient has particular medical conditions.
Dose modification should be managed by the treating specialist.
Depending on the circumstances, the healthcare professional may recommend:
- Continuing the current dose.
- Temporarily interrupting treatment.
- Reducing the dose.
- Restarting treatment after symptoms improve.
- Permanently discontinuing treatment when necessary.
Patients should never increase, reduce or restart pemigatinib independently.
8. Blood Phosphate Monitoring
Pemigatinib can increase phosphate levels in the blood.
This adverse reaction is known as hyperphosphatemia. It is an important safety concern because excessive phosphate levels may contribute to mineral deposits in soft tissues.
Blood phosphate testing is therefore an important part of treatment monitoring.
Depending on the results, the treating specialist may recommend dietary phosphate management, phosphate-lowering medication or treatment modification.
Patients should attend scheduled laboratory appointments even if they feel well.
9. Eye Examinations During Treatment
Pemigatinib can cause ocular adverse reactions, including retinal pigment epithelial detachment.
Before starting treatment, patients should receive an appropriate eye examination, including optical coherence tomography, under U.S. reference-product instructions.
Follow-up examinations are recommended every two months during the first six months and every three months afterward while treatment continues.
Patients should promptly report blurred vision, new floaters, flashes of light or other visual changes.
A new visual symptom should not be ignored until the next routine appointment.
10. Review Other Medicines
Pemigatinib may interact with medicines that affect CYP3A enzymes.
Strong or moderate CYP3A inducers may reduce pemigatinib exposure, while strong or moderate CYP3A inhibitors may increase exposure.
Patients should tell their healthcare professional about all prescription medicines, nonprescription products, supplements and herbal preparations they use.
They should not begin or stop another medicine without checking whether an interaction is possible.
11. Pregnancy and Breastfeeding
Pemigatinib may cause harm to an unborn baby.
Patients who are pregnant, planning pregnancy or potentially able to become pregnant should discuss the risks with their healthcare professional before treatment.
Under U.S. reference-product instructions, females of reproductive potential should use effective contraception during treatment and for one week after the final dose.
Breastfeeding considerations should also be discussed with the treating specialist. Patients should not assume that breastfeeding is safe during treatment.
12. Storage and Handling
Patients should store the medicine according to the instructions on the actual product packaging.
Keep the medicine in its original packaging when instructed, protect it from unsuitable environmental conditions and keep it out of the reach of children.
Do not use tablets that appear damaged, altered or inconsistent with the supplied product information.
Expired or unwanted medicine should be disposed of according to local pharmaceutical disposal guidance.
13. Keep a Treatment Record
A treatment record can help patients and healthcare professionals follow the prescribed schedule.
It may include:
- Date and time of each dose.
- Scheduled treatment-free days.
- Missed doses.
- Vomiting after a dose.
- New symptoms.
- Blood test appointments.
- Eye examination dates.
- Other medicines being taken.
Patients should bring relevant treatment information to medical appointments.
14. When to Contact a Healthcare Professional
Patients should report persistent diarrhea, vomiting, mouth inflammation, nail problems, skin reactions, unusual fatigue or other symptoms that affect daily activities.
New visual changes require prompt medical attention.
Severe or rapidly worsening symptoms should be assessed urgently.
Conclusion
Taking Pemitinib correctly requires following the prescribed dose, treatment schedule and monitoring plan.
The U.S. reference-product instructions describe different schedules for different indications. Patients must use only the schedule prescribed for their particular condition.
Missed doses, vomiting, adverse reactions and potential drug interactions should be managed according to official product instructions and professional advice. Never change the dose or treatment schedule independently.